title: Meal-induced insulin sensitization is preserved after acute olanzapine administration in female Sprague-Dawley rats.
abstract: Olanzapine, an atypical antipsychotic, can acutely induce fasting insulin resistance, but we do not know whether it is able to modulate the meal-induced insulin sensitization (MIS). Two main experimental groups (control and olanzapine-treated) were created with two subgroups (fasted and re-fed) within each. After oral vehicle/olanzapine administration, the first meal size and duration and the total amount of consumed food was recorded in conscious rats. Then, under anaesthesia, the carotid artery and jugular vein was prepared and cannulated to obtain samples for blood glucose and hormone determination as well as for insulin/glucose infusion, respectively. Basal insulin sensitivity and MIS was determined by homeostasis model assessment (HOMA) calculation and by rapid insulin sensitivity test, respectively. In fasted animals, olanzapine increased blood glucose and plasma insulin and reduced basal insulin sensitivity, but it failed to modify other hormone levels. Postprandial leptin and glucose-dependent insulinotropic polypeptide (GIP) levels increased, and ghrelin level decreased significantly (p < 0.05) both in vehicle- and olanzapine-treated groups, but plasma insulin increased only in vehicle-treated animals. Furthermore, decrement in ghrelin level was attenuated in olanzapine-treated animals compared to controls. There was no significant change in the first meal size and duration or in the total amount of food consumed. Olanzapine had no effect on the MIS. We demonstrated that olanzapine can induce insulin resistance without weight gain in healthy rats. Furthermore, the MIS was preserved after acute olanzapine treatment. The blunted postprandial ghrelin and insulin response could contribute to the effect of olanzapine on feeding behaviour. Pharmacological induction of MIS may improve the olanzapine-induced insulin resistance.
authors: Department of Pharmacology and Pharmacotherapy, University of Debrecen, Faculty of Medicine, Nagyerdei blvd. 98., Debrecen, 4032, Hungary.
authors: Diána
authors: D
authors: Kovács
authors: Csaba
authors: C
authors: Hegedűs
authors: Rita
authors: R
authors: Kiss
authors: Réka
authors: R
authors: Sári
authors: József
authors: J
authors: Németh
authors: Zoltán
authors: Z
authors: Szilvássy
authors: Barna
authors: B
authors: Peitl
mesh_terms: D000818:Animals; D001569:Benzodiazepines / Q000494:pharmacology*; D001786:Blood Glucose / Q000378:metabolism; D001835:Body Weight / Q000187:drug effects*; D002149:Energy Intake / Q000187:drug effects*; D005215:Fasting; D005247:Feeding Behavior / Q000187:drug effects*; D005260:Female; D054439:Ghrelin / Q000097:blood; D005951:Glucose Tolerance Test; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance; D020738:Leptin / Q000097:blood; D000077152:Olanzapine; D019518:Postprandial Period; D017207:Rats, Sprague-Dawley
chemical_list: D001786:Blood Glucose; D054439:Ghrelin; D007328:Insulin; D020738:Leptin; D001569:Benzodiazepines; D000077152:Olanzapine
references: Metabolism. 2005 May;54(5):579-83
references: 15877286
references: J Clin Psychiatry. 2001 Apr;62(4):231-8
references: 11379836
references: Auton Neurosci. 2002 Jan 10;95(1-2):125-30
references: 11871777
references: Metabolism. 2007 Jul;56(7):863-4
references: 17570243
references: Drug Metab Pharmacokinet. 2005 Oct;20(5):368-78
references: 16272755
references: Diabetes. 2013 Sep;62(9):3232-40
references: 23835329
references: Behav Brain Res. 2004 Jun 4;152(1):121-7
references: 15135975
references: Eur J Pharmacol. 2007 Jul 30;568(1-3):287-8
references: 17521627
references: Int J Obes (Lond). 2012 Feb;36(2):254-61
references: 21556042
references: J Pharmacol Exp Ther. 2010 Jul;334(1):164-70
references: 20413600
references: Eur J Endocrinol. 2010 Jan;162(1):75-83
references: 19779025
references: Can J Physiol Pharmacol. 2011 Feb;89(2):135-42
references: 21326345
references: Pediatr Diabetes. 2003 Sep;4(3):119-25
references: 14655269
references: Arch Gen Psychiatry. 2005 Jan;62(1):19-28
references: 15630069
references: Pharmacol Biochem Behav. 2002 Jan-Feb;71(1-2):147-54
references: 11812517
references: Schizophr Res. 2011 Sep;131(1-3):90-5
references: 21696923
references: Schizophr Res. 2010 Nov;123(2-3):225-33
references: 20692814
references: Proc West Pharmacol Soc. 1997;40:19-20
references: 9436202
references: Can J Physiol Pharmacol. 1999 Aug;77(8):553-62
references: 10543718
references: Behav Brain Res. 2011 Mar 1;217(2):337-46
references: 21056063
references: CNS Drugs. 2013 Dec;27(12):1069-80
references: 24114586
references: J Pharmacol Sci. 2004 May;95(1):9-17
references: 15153645
references: Life Sci. 2007 Sep 1;81(12 ):1024-30
references: 17822717
references: Am J Psychiatry. 2000 Jun;157(6):975-81
references: 10831479
references: Arch Gen Psychiatry. 2002 Apr;59(4):337-45
references: 11926934
references: Neuropsychopharmacology. 2007 Feb;32(2):289-97
references: 17035934
references: Br J Pharmacol. 2003 Jul;139(6):1171-9
references: 12871836
references: Schizophr Res. 2008 Sep;104(1-3):23-30
references: 18675538
references: Psychopharmacology (Berl). 2005 Aug;181(1):80-9
references: 15778884
references: Diabet Med. 2002 Jul;19(7):527-34
references: 12099954
references: Eur Neuropsychopharmacol. 2012 May;22(5):364-73
references: 21982116
references: CNS Drugs. 2005;19 Suppl 1:1-93
references: 15998156
references: Am J Psychiatry. 1999 Nov;156(11):1686-96
references: 10553730
references: Biopharm Drug Dispos. 1999 Nov;20(8):369-77
references: 10870093
references: Circ Res. 1980 Jul;47(1):1-9
references: 7379260
references: J Clin Endocrinol Metab. 2001 Oct;86(10):4615-7
references: 11600512
references: Proc West Pharmacol Soc. 1994;37:39-40
references: 7984665
references: Diabetologia. 1985 Jul;28(7):412-9
references: 3899825
references: Metabolism. 2009 Mar;58(3):328-32
references: 19217447